Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: serotonin 6 receptor antagonists - Suven Life Sciences

Drug Profile

Research programme: serotonin 6 receptor antagonists - Suven Life Sciences

Alternative Names: 5HT6 compounds; SUVN-501; SUVN-504; SUVN-507; SUVN-512; SUVN-623; SUVN-901; SUVN-976

Latest Information Update: 03 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suven Life Sciences
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Carbazoles; Indoles; Neuroprotectants; Obesity therapies; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cognition disorders; Huntington's disease; Parkinson's disease; Schizophrenia
  • No development reported Obesity

Most Recent Events

  • 22 Aug 2018 Suven Life Sciences has patent protection corresponding to new chemical entities covering the class of selective 5-HT6 compounds for the treatment of neurodegenerative disorders in Canada and USA
  • 12 Jun 2018 Suven Life Sciences has patent protection for 5-HT4 and 5-HT6 compounds in China and USA
  • 22 May 2018 Suven Life Sciences secures product patents for 5-HT6 compounds in Norway and New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top